Efficiency and safety of percutaneous ultrasound-guided radiofrequency ablation for right adrenal metastases from hepatocellular carcinoma

Q4 Medicine 中华超声影像学杂志 Pub Date : 2020-02-25 DOI:10.3760/CMA.J.ISSN.1004-4477.2020.02.009

Baoxian Liu, Yangyang Lei, Yang Tan, Xiaohua Xie, Jingzhi Huang, Xiaohui Xie

{"title":"Efficiency and safety of percutaneous ultrasound-guided radiofrequency ablation for right adrenal metastases from hepatocellular carcinoma","authors":"Baoxian Liu, Yangyang Lei, Yang Tan, Xiaohua Xie, Jingzhi Huang, Xiaohui Xie","doi":"10.3760/CMA.J.ISSN.1004-4477.2020.02.009","DOIUrl":null,"url":null,"abstract":"Objective \nTo retrospectively summarize and evaluate the efficiency and safety of percutaneous ultrasound-guided radiofrequency ablation (RFA) for adrenal metastasis (AM) from hepatocellular carcinoma (HCC). \n \n \nMethods \nFrom October 2009 to September 2018, 16 patients with AM from HCC who underwent percutaneous RFA in the First Affiliated Hospital of Sun Yat-Sen University were enrolled in the study. The complete ablation and local tumor progression rates were elevated, and the side effects and complications were summarized. \n \n \nResults \nThe median ablation time of AM was 16 min. The complete ablation rate was 87.5% (14/16). After the follow-up period of 3 to 55 months, among the patients with complete ablation, there were 3 patients were detected local tumor progression (LTP), the LTP rate was 21.4% (3/14). As for the side effects and complications, 3 patients were diagnosed as hypertension crisis (3/16, 18.8%), 2 showed reduced heart rate and 1 of them exhibited frequent premature ventricular contraction which resulted in termination of ablation. There was no ablation-related death or adrenal failure. \n \n \nConclusions \nPercutaneous US-guided RFA is safe and effective in the treatment of AM originated from HCC. \n \n \nKey words: \nRadiofrequency ablation; Hepatocellular carcinoma; Adrenal metastasis","PeriodicalId":10224,"journal":{"name":"中华超声影像学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华超声影像学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4477.2020.02.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To retrospectively summarize and evaluate the efficiency and safety of percutaneous ultrasound-guided radiofrequency ablation (RFA) for adrenal metastasis (AM) from hepatocellular carcinoma (HCC). Methods From October 2009 to September 2018, 16 patients with AM from HCC who underwent percutaneous RFA in the First Affiliated Hospital of Sun Yat-Sen University were enrolled in the study. The complete ablation and local tumor progression rates were elevated, and the side effects and complications were summarized. Results The median ablation time of AM was 16 min. The complete ablation rate was 87.5% (14/16). After the follow-up period of 3 to 55 months, among the patients with complete ablation, there were 3 patients were detected local tumor progression (LTP), the LTP rate was 21.4% (3/14). As for the side effects and complications, 3 patients were diagnosed as hypertension crisis (3/16, 18.8%), 2 showed reduced heart rate and 1 of them exhibited frequent premature ventricular contraction which resulted in termination of ablation. There was no ablation-related death or adrenal failure. Conclusions Percutaneous US-guided RFA is safe and effective in the treatment of AM originated from HCC. Key words: Radiofrequency ablation; Hepatocellular carcinoma; Adrenal metastasis

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

经皮超声引导射频消融治疗肝细胞癌右肾上腺转移瘤的有效性和安全性

目的回顾性总结和评价经皮超声引导射频消融（RFA）治疗肝细胞癌（HCC）肾上腺转移（AM）的有效性和安全性。方法选择2009年10月至2018年9月在中山大学附属第一医院接受经皮RFA治疗的16例原发性肝癌AM患者。完全消融和局部肿瘤进展率升高，并总结了副作用和并发症。结果AM的中位消融时间为16min，完全消融率为87.5%（14/16）。经过3至55个月的随访，在完全消融的患者中，有3名患者检测到局部肿瘤进展（LTP），LTP发生率为21.4%（3/14）。在副作用和并发症方面，3名患者被诊断为高血压危象（3/16，18.8%），2名患者心率减慢，其中1名患者出现频繁的室性早搏，导致消融终止。没有消融相关的死亡或肾上腺功能衰竭。结论经皮超声引导下RFA治疗原发性肝癌AM安全有效。关键词：射频消融；肝细胞癌；肾上腺转移

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊